Abstract Number: 1179 • 2019 ACR/ARP Annual Meeting
Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis
Background/Purpose: Background/Purpose: Discriminating inflammatory pain from non-inflammatory pain is critical to determine therapeutic strategy in inflammatory arthritis (IA) such as rheumatoid arthritis (RA) and spondyloarthritis…Abstract Number: 1247 • 2019 ACR/ARP Annual Meeting
Adult-Onset Still’s Disease and Spondyloarthritis: Overlapping Syndrome or Incidental Association? A Series of 5 Cases
Background/Purpose: Some forms of spondyloarthritis (SpA) such as SAPHO syndrome are classified as auto-inflammatory disorders. Association with adult onset Still’s disease (AoSD) has never been…Abstract Number: 1486 • 2019 ACR/ARP Annual Meeting
Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Background/Purpose: Infliximab (Ifx) has proven to be efficacious for improving symptoms in patients with axial SpA(axSpA). Several factors may influence the pharmacokinetic-pharmacodynamic of Ifx and…Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…Abstract Number: 1781 • 2019 ACR/ARP Annual Meeting
Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis
Background/Purpose: Enthesis-resident CD4-CD8- double-negative (DN) T cells have been implicated in the pathogenesis of spondyloarthritis. Overexpression of IL-23 in adult mice activates these cells to…Abstract Number: 2574 • 2018 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in treating patients with axial spondyloarthritis (axSpA), but they are associated with adverse effects and high costs.…Abstract Number: 687 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Spondyloarthritis Patients in Japan in Comparison to Other Regions of the World
Background/Purpose: To delineateclinical characteristicsof patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world. Methods: Utilizingthe COMOSPA data, an international cross-sectional…Abstract Number: 1613 • 2018 ACR/ARHP Annual Meeting
Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort
Background/Purpose: Dactylitis is a particular feature shared across the several phenotypical forms of spondyloarthritis (SpA), part of the classification criteria. There are only few data…Abstract Number: 1622 • 2018 ACR/ARHP Annual Meeting
ASAS Consensus on Spanish Nomenclature for Spondyloarthritis
Background/Purpose: In the last three decades, major advances in the spondyloarthritis (SpA) field have been achieved leading to new terminology. Whilst this terminology is well…Abstract Number: 1516 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
Background/Purpose: Uveitis is a common extra-articular manifestation in patients with spondyloarthritis (SpA) requiring, in most severe cases, the use of biological therapy, especially tumour necrosis…Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…Abstract Number: 2801 • 2017 ACR/ARHP Annual Meeting
Effects of Anti-IL17 Blockade with Secukinumab on Systemic and Local Immune Responses: A Mechanism-of-Action Study in Peripheral Spondyloarthritis
Background/Purpose: IL-17A blockade is an effective therapy for AS and PsA, the prototypical forms of spondyloarthritis(SpA). How IL-17A blockade affects the systemic and local immune…Abstract Number: 2821 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Telemedicine Program for Identification of Spondyloarthritis in Medically Underserviced Communities
Background/Purpose: Early diagnosis is critical for optimal management of patients with inflammatory arthritis. Axial spondyloarthritis (AxSpA) has the longest delay in diagnosis among inflammatory joint…Abstract Number: 711 • 2016 ACR/ARHP Annual Meeting
The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting
Background/Purpose: Inflammatory back pain (IBP) as a symptom has been shown to perform effectively for selecting patients in primary care / orthopaedic settings for referral…Abstract Number: 723 • 2016 ACR/ARHP Annual Meeting
Hip Disease Treatment and Progression in Ankylosing Spondylitis
Methods: We included 613 AS patients meeting the modified New York criteria and had at least 2 sets of hip radiographs. Using the Bath Ankylosing…